Akreos® MICS™

Hydrophilic Acrylic IOL

MONOFOCAL MICRO-INCISION

An aspheric, aberration-free optic constructed of flexible material for micro-incision cataract surgery.

ADVANCED
OPTICS

INCISION SIZE
AS SMALL AS **1.8MM**[1]

The haptics provide four points of capsular bag contact designed for optimal centration and stability.

The Akreos advanced optic provided patients quality contrast sensitivity and less negative dyphotopsia post-op results compared to a standard hydrophobic acrylic IOL.[1]

97.1% of patients in a clinical study achieved a BCVA of 20/40 or better within 1 year post-surgery.[2]

BAUSCH + LOMB

Akreos® MICS™

LEARN MORE AT **bauschsurgical.com**

MI60L order number MI60LPXXXX



MODEL NUMBER	MI60L (non-preload)
OPTIC DESIGN	One-piece Hydrophilic acrylic Aspheric, aberration-free, biconvex
OPTIC SIZE	5.6mm—22.5 to 30.0 D 6.0mm—15.5 to 22.0 D 6.2mm—0.0 to 15.0 D
LENGTH	10.5mm—22.5 to 30.0 D 10.7mm—15.5 to 22.0 D 11.0mm—0.0 to 15.0 D
HAPTICS	4 haptics
OPTICAL BIOMETRY SUGGESTED A-CONSTANT ACD-CONSTANT*	119.1 5.61mm 1.85mm
APPLANATION SUGGESTED A-CONSTANT ACD-CONSTANT SURGEON FACTOR	118.4 5.20mm 1.45mm
OTHER FEATURES	Refractive index: 1.46 UV absorbing 360° posterior square edge
DIOPTER RANGE	0 to +10 D in 1.0-D increments +10 to +30 D in 0.5-D increments

VIS100 Inserter

FOR INSERTING LENS MODEL MI60L
RECOMMENDED INCISION SIZE 1.8mm-2.4mm
TYPE OF ACTION Push-type
COMMENTS Single-handed delivery. Disposable.

1. Radford S, Carlsson A, Barrett G. Comparison of pseudophakic dyphotopsia with Akreos Adapt and SN60-AT intraocular lenses. J Cataract Refract Surg 2007; 33:88-93.
2. Akreos / Akreos MICs Directions for Use.

Indications and Important Safety Information for Akreos® Intraocular Lens

INDICATIONS: Akreos® posterior chamber intraocular lenses are indicated for primary implantation for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed by phacoemulsification. The lens is intended for placement in the capsular bag.

CONTRAINDICATIONS: Implantation is not advisable when the IOL may aggravate an existing condition, interfere with the diagnosis or treatment of a pathology, or present a risk to the sight of the patient. These conditions are uncontrolled glaucoma, rubeotic cataract, retinal detachment, atrophy of the iris, microphthalmia, developing chronic eye infections, endothelial corneal dystrophy, perioperative complications (such as vitreous loss, hemorrhage, etc), foreseeable post-operative complications.

WARNINGS: Before implanting Akreos® lenses in patients, preoperative evaluation should be performed by a surgeon to consider the potential benefit/risk ratio. There are insufficient clinical data to demonstrate safety and efficacy for placement in the ciliary sulcus. Improper handling or folding techniques may cause damage to the haptic or optic portions of the lenses. Use only validated folding instruments. Exercise care during handling and insertion to avoid permanent forceps marks in the central optic zone.

PRECAUTIONS: Do not attempt to resterilize these lenses. Do not store the IOL package in direct sunlight or at a temperature below freezing (<0°C). Avoid high temperatures (>45°C). Do not reuse the IOL. Do not soak or rinse lenses in solutions other than balanced salt solution or equivalent. Akreos® lenses can absorb substances that they contact (disinfectant, drug). Do not place the lens in contact with surfaces where such contamination can occur.

ADVERSE EVENTS: The incidence of adverse events experienced during the clinical trial, including hyphema, macular edema, retinal detachment, etc., was comparable to or lower than the incidence reported in the historic control ("FDA grid") population.

ATTENTION: Refer to the Directions for Use labeling for a complete listing of indications, warnings and precautions, clinical trial information, etc.

CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a physician.